LLY
StockEli Lilly and Co
- HQ
- US
- Sector
- Pharmaceuticals
- Issued
- 1985-01-13
- Shares out.
- 942M
Performance
1 h agoKey statistics
1 h ago- Market cap
- $1.01T
- Enterprise value
- $1.04T
- P/E (TTM)
- 39.81
- Forward P/E
- 27.51
- P/E (annual)
- 48.75
- PEG
- 1.37
- P/B
- 38.29
- P/S (TTM)
- 13.93
- P/S (annual)
- 15.44
- EV / EBITDA
- 31.11×
- EV / Revenue
- 14.45×
- EPS (TTM)
- $28.15
- EPS (annual)
- $22.95
- Basic EPS (TTM)
- $28.15
- Book value / share
- $28.09
- Gross margin
- 82.83%
- Operating margin
- 43.63%
- Net margin
- 34.99%
- Return on equity (ROE)
- 101.31%
- Return on assets (ROA)
- 22.73%
- Return on investment (ROI)
- 37.71%
- EBITDA / share
- $37.37
- Revenue / share (TTM)
- $80.64
- Revenue growth (TTM YoY)
- +47.44%
- Revenue growth (Q YoY)
- +55.55%
- EPS growth (TTM YoY)
- +128.83%
- Dividend yield (indicated)
- 0.64%
- Dividend yield (TTM)
- 0.56%
- Dividend / share (TTM)
- $5.91
- Payout ratio
- 22.10%
- Current ratio
- 1.58
- Quick ratio
- 0.78
- Debt / equity
- 1.60
- LT debt / equity
- 1.54
- Beta
- 0.52
- Volatility (3M)
- 37.57%
Analyst ratings
1 h agoEarnings
1 h agoRelated news
1 h ago- Yahoo·5 d agocompanyCVS will add these weight-loss options to drug plans
CVS Health will reinstate coverage of Eli Lilly's weight-loss injectable Zepbound and begin coverage of the anti-obesity pill Foundayo.
- SeekingAlpha·5 d agocompanyEli Lilly and Company (LLY) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Eli Lilly and Company (LLY) Bernstein 42nd Annual Strategic Decisions Conference May 28, 2026 1:30 PM EDTCompany ParticipantsDaniel Skovronsky - Chief...
- Yahoo·5 d agocompanyLilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), Mounjaro (tirzepatide), Foundayo (orforglipron) and retatrutide, will present new data across its cardiometabolic portfolio at the American Diabetes Association's 86th Scientific Sessions taking place June 5-8 in New Orleans. Together, these findings position Lilly to lead the next era of cardiometabolic care, with a differentiated suite of approved and investigational medicines built to expand choice for the millions living
- Yahoo·5 d agocompanyAAHI’s SLA-SE Adjuvant Technology Powers Lilly’s Acquisition of Curevo’s Next-Generation Shingles Vaccine
SEATTLE, May 28, 2026--The Access to Advanced Health Institute (AAHI), a nonprofit biotech organization dedicated to developing vaccines and technologies for global health, today congratulates Eli Lilly and Company and Curevo Vaccine on Lilly’s acquisition of Curevo.
- Yahoo·5 d agocompanyLLY Stock Hits All-Time High — CVS Coverage Boost For Zepbound May Be Driving Gains
CVS Health’s decision to expand formulary coverage for key GLP-1 therapies marks a boost for Eli Lilly's obesity drug business.
- Yahoo·5 d agocompanyEli Lilly Stock Heads for Record Close. CVS Weight-Loss Drug Coverage Drives It Higher.
CVS Health’s Caremark will resume insurance coverage of Eli Lilly’s Zepbound and separately begin covering its Foundayo weight-loss pill.
- Yahoo·5 d agocompanyTop Midday Stories: US Reportedly Reaches Deal With Iran, Needs Trump's Approval; Caesars to be Acquired by Fertitta for $17.6 Billion
The S&P 500 and Nasdaq Composite were up, while the Dow Jones Industrial Average was down slightly i
- Benzinga·5 d agocompanyWhy Is Eli Lilly Stock Surging On Thursday?
Eli Lilly (NYSE:LLY) shares jumped on Thursday morning after securing expanded PBM coverage for its blockbuster obesity treatments, Zepbound and Foundayo.
